Diversify Advisory Services LLC Purchases Shares of 16,755 Stevanato Group S.p.A. (NYSE:STVN)

Diversify Advisory Services LLC acquired a new stake in Stevanato Group S.p.A. (NYSE:STVN) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,755 shares of the company’s stock, valued at approximately $525,000.

Several other institutional investors have also recently modified their holdings of the company. First Light Asset Management LLC increased its holdings in Stevanato Group by 24.8% in the 4th quarter. First Light Asset Management LLC now owns 729,961 shares of the company’s stock worth $19,921,000 after buying an additional 145,206 shares during the period. Yorktown Management & Research Co Inc acquired a new stake in shares of Stevanato Group in the fourth quarter worth $254,000. Trust Point Inc. purchased a new position in shares of Stevanato Group during the fourth quarter worth $252,000. Riverbridge Partners LLC lifted its position in Stevanato Group by 78.1% during the fourth quarter. Riverbridge Partners LLC now owns 1,274,805 shares of the company’s stock valued at $34,789,000 after purchasing an additional 559,070 shares during the period. Finally, Sands Capital Management LLC boosted its holdings in Stevanato Group by 1.6% in the fourth quarter. Sands Capital Management LLC now owns 1,884,330 shares of the company’s stock valued at $51,423,000 after purchasing an additional 29,450 shares during the last quarter.

Wall Street Analysts Forecast Growth

STVN has been the subject of a number of recent research reports. Morgan Stanley reiterated an “equal weight” rating and set a $30.00 price objective on shares of Stevanato Group in a research note on Monday, April 22nd. Stephens reissued an “overweight” rating and issued a $38.00 price target on shares of Stevanato Group in a report on Monday, March 25th. Finally, BNP Paribas started coverage on shares of Stevanato Group in a research note on Monday, April 22nd. They set an “outperform” rating on the stock. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Stevanato Group presently has a consensus rating of “Moderate Buy” and a consensus target price of €34.17 ($36.74).

Stevanato Group Price Performance

STVN stock traded up €0.55 ($0.59) during mid-day trading on Friday, reaching €18.53 ($19.92). 272,000 shares of the company’s stock were exchanged, compared to its average volume of 566,745. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.35 and a current ratio of 1.92. Stevanato Group S.p.A. has a 12-month low of €16.56 ($17.81) and a 12-month high of €36.30 ($39.03). The stock’s 50 day moving average is €20.38 and its 200 day moving average is €26.52.

Stevanato Group (NYSE:STVN) last announced its earnings results on Thursday, May 9th. The company reported €0.09 ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.12 ($0.13) by (€0.03) (($0.03)). The business had revenue of €256.24 million for the quarter, compared to analysts’ expectations of €261.28 million. Stevanato Group had a net margin of 12.57% and a return on equity of 12.61%. Equities research analysts anticipate that Stevanato Group S.p.A. will post 0.54 EPS for the current fiscal year.

Stevanato Group Dividend Announcement

The business also recently announced an annual dividend, which will be paid on Monday, July 15th. Stockholders of record on Tuesday, June 4th will be paid a dividend of $0.053 per share. The ex-dividend date is Tuesday, June 4th. This represents a dividend yield of 0.29%. Stevanato Group’s dividend payout ratio is currently 10.91%.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.